参考文献
关键文献
McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Jul;106(1):16-22. 摘要
Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005 Aug 6-12;366(9484):491-505. 摘要
Obermair A, Janda M, Baker J, et al. Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: results from a randomised controlled trial. Eur J Cancer.2012 May;48(8):1147-53.全文 摘要
Nout RA, Putter H, Jürgenliemk-Schulz IM, et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer. 2012 Jul;48(11):1638-48.全文 摘要
de Boer SM, Powell ME, Mileshkin L, et al; PORTEC Study Group. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Feb 12;19(3):295-309.全文 摘要
参考文献
1. World Health Organization. Tumours of the uterine corpus. In: WHO Classification of Tumours Editorial Board, eds. Female genital tumours. WHO classification of tumours, 5th edition, volume 4. Lyon, France: IARC; 2020.全文
2. Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol. 2004 May;11(3):117-42. 摘要
3. Fadare O, Liang SX, Ulukus EC, et al. Precursors of endometrial clear cell carcinoma. Am J Surg Pathol. 2006 Dec;30(12):1519-30. 摘要
4. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005 Sep 15;11(18):6422-30.全文 摘要
5. Hoffman K, Nekhlyudov L, Deligdisch L. Endometrial carcinoma in elderly women. Gynecol Oncol. 1995 Aug;58(2):198-201. 摘要
6. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009 May;105(2):103-4. [Erratum in: Int J Gynaecol Obstet. 2010 Feb;108(2):176.] 摘要
7. Koskas M, Amant F, Mirza MR, et al. Cancer of the corpus uteri: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):45-60.全文 摘要
8. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983 Feb;15(1):10-7. 摘要
9. Ryan AJ, Susil B, Jobling TW, et al. Endometrial cancer. Cell Tissue Res. 2005 Oct;322(1):53-61. 摘要
10. Santin AD. HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? Gynecol Oncol. 2003 Mar;88(3):263-5. 摘要
11. Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet. 1997 Oct;17(2):143-4. 摘要
12. Risinger JI, Hayes AK, Berchuck A, et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997 Nov 1;57(21):4736-8.全文 摘要
13. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000 Feb 15;88(4):814-24. 摘要
14. Reinartz JJ, George E, Lindgren BR, et al. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol. 1994 Oct;25(10):1075-83. 摘要
15. Rolitsky CD, Theil KS, McGaughy VR, et al. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol. 1999 Apr;18(2):138-43. 摘要
16. Santin AD, Bellone S, Van Stedum S, et al. Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol. 2005 Jul;98(1):24-30. 摘要
17. Slomovitz BM, Broaddus RR, Burke TW, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004 Aug 1;22(15):3126-32.全文 摘要
18. Hetzel DJ, Wilson TO, Keeney GL, et al. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol. 1992 Nov;47(2):179-85. 摘要
19. Kandoth C, Schultz N, et al; Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 2;497(7447):67-73. [Erratum in: Nature. 2013 Aug 8;500(7461):242.]全文 摘要
20. Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017 Mar 1;123(5):802-13.全文 摘要
21. Clarke MA, Long BJ, Del Mar Morillo A, et al. Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. JAMA Intern Med. 2018 Sep 1;178(9):1210-22.全文 摘要
22. Lachance JA, Everett EN, Greer B, et al. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol. 2006 Jun;101(3):470-5. 摘要
23. Soliman PT, Oh JC, Schmeler KM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005 Mar;105(3):575-80. 摘要
24. Gu M, Shi W, Barakat RR, et al. Pap smears in women with endometrial carcinoma. Acta Cytol. 2001 Jul-Aug;45(4):555-60. 摘要
25. Eddy GL, Wojtowycz MA, Piraino PS, et al. Papanicolaou smears by the Bethesda system in endometrial malignancy: utility and prognostic importance. Obstet Gynecol. 1997 Dec;90(6):999-1003. 摘要
26. Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol. 2016 Nov 7;34(35):4225-30.全文 摘要
27. Kocarnik JM, Compton K, Dean FE, et al; Global Burden of Disease 2019 Cancer Collaboration. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022 Mar 1;8(3):420-44.全文 摘要
28. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209-49.全文 摘要
29. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7-33.全文 摘要
30. National Cancer Institute. Surveillance epidemiology and end results (SEER). Cancer stat facts: uterine cancer. 2022 [internet publication].全文
31. Clarke MA, Devesa SS, Hammer A, et al. Racial and ethnic differences in hysterectomy-corrected uterine corpus cancer mortality by stage and histologic subtype. JAMA Oncol. 2022 Jun 1;8(6):895-903. 摘要
32. World Health Organization: Global Cancer Observatory. Cancer today. 2020 [internet publication].全文
33. Horn LC, Meinel A, Handzel R, et al. Histopathology of endometrial hyperplasia and endometrial carcinoma: an update. Ann Diagn Pathol. 2007 Aug;11(4):297-311. 摘要
34. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985 Jul 15;56(2):403-12.全文 摘要
35. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008 May;21(5):591-8.全文 摘要
36. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995 Feb;85(2):304-13. 摘要
37. Marjoribanks J, Farquhar C, Roberts H, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017 Jan 17;(1):CD004143.全文 摘要
38. Koornstra JJ, Mourits MJ, Sijmons RH, et al. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol. 2009 Apr;10(4):400-8. 摘要
39. Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet. 2009 Feb;75(2):141-9. 摘要
40. Lynch HT, Krush AJ, Lemon HM, et al. Tumor variation in families with breast cancer. JAMA. 1972 Dec 25;222(13):1631-5. 摘要
41. Win AK, Reece JC, Ryan S. Family history and risk of endometrial cancer: a systematic review and meta-analysis. Obstet Gynecol. 2015 Jan;125(1):89-98. 摘要
42. Hemminki K, Granstrom C. Familial clustering of ovarian and endometrial cancers. Eur J Cancer. 2004 Jan;40(1):90-5. 摘要
43. Lu KH, Schorge JO, Rodabaugh KJ, et al. Prospective determination of prevalence of Lynch II syndrome in young women with endometrial cancer. J Clin Oncol. 2007 Nov 20;25(33):5158-64. 摘要
44. Thompson D, Easton DF; Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002 Sep 18;94(18):1358-65.全文 摘要
45. Chubak J, Tworoger SS, Yasui Y, et al. Associations between reproductive and menstrual factors and postmenopausal sex hormone concentrations. Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1296-301. 摘要
46. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000 Jun 7;92(11):924-30.全文 摘要
47. Dinulescu DM, Ince TA, Quade BJ, et al. Role of K-ras and PTEN in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med. 2005 Jan;11(1):63-70. 摘要
48. Leskela S, Pérez-Mies B, Rosa-Rosa JM, et al. Molecular basis of tumor heterogeneity in endometrial carcinosarcoma. Cancers (Basel). 2019 Jul 9;11(7):964.全文 摘要
49. Deshpande M, Romanski PA, Rosenwaks Z, et al. Gynecological cancers caused by deficient mismatch repair and microsatellite instability. Cancers (Basel). 2020 Nov 10;12(11):3319.全文 摘要
50. Kim SR, Pina A, Albert A, et al. Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers. Int J Gynecol Cancer. 2020 Jun;30(6):783-8. 摘要
51. Ferriss JS, Erickson BK, Shih IM, et al. Uterine serous carcinoma: key advances and novel treatment approaches. Int J Gynecol Cancer. 2021 Aug;31(8):1165-74.全文 摘要
52. O'Mara TA, Glubb DM, Amant F, et al. Identification of nine new susceptibility loci for endometrial cancer. Nat Commun. 2018 Aug 9;9(1):3166.全文 摘要
53. Crosbie EJ, Roberts C, Qian W, et al. Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial. Eur J Cancer. 2011 Nov 17;48(6):853-64.全文 摘要
54. Modesitt SC, Tian C, Kryscio R, et al. Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Apr;105(1):59-65. 摘要
55. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007 Dec 1;335(7630):1134.全文 摘要
56. Jenabi E, Poorolajal J. The effect of body mass index on endometrial cancer: a meta-analysis. Public Health. 2015 Jul;129(7):872-80. 摘要
57. Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst. 1996 Aug 21;88(16):1127-35.全文 摘要
58. Duska L, Shahrokni A, Powell M. Treatment of older women with endometrial cancer: improving outcomes with personalized care. Am Soc Clin Oncol Educ Book. 2016 May 19;35:164-74.全文 摘要
59. Royal College of Obstetricians and Gynaecologists. Management of endometrial hyperplasia (green-top guideline no. 67). Feb 2016 [internet publication].全文
60. Travaglino A, Raffone A, Saccone G, et al. Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: a specific marker of precancer and novel indication for treatment. A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2018 Dec;97(12):1415-26.全文 摘要
61. Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006 Feb 15;106(4):812-9.全文 摘要
62. Travaglino A, Raffone A, Saccone G, et al. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019 Apr;74(5):676-87. 摘要
63. Raglan O, Kalliala I, Markozannes G, et al. Risk factors for endometrial cancer: an umbrella review of the literature. Int J Cancer. 2019 Oct 1;145(7):1719-30.全文 摘要
64. Wu Y, Sun W, Liu H, et al. Age at menopause and risk of developing endometrial cancer: a meta-analysis. Biomed Res Int. 2019 May 29;2019:8584130.全文 摘要
65. Michels KA, Pfeiffer RM, Brinton LA, et al. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA Oncol. 2018 Apr 1;4(4):516-21.全文 摘要
66. Karlsson T, Johansson T, Höglund J, et al. Time-dependent effects of oral contraceptive use on breast, ovarian, and endometrial cancers. Cancer Res. 2021 Feb 15;81(4):1153-62.全文 摘要
67. Neven P, De Muylder X, Van Belle Y, et al. Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet. 1998 Jan 3;351(9095):36. 摘要
68. Magriples U, Naftolin F, Schwartz PE, et al. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 1993 Mar;11(3):485-90. 摘要
69. Ferguson SE, Soslow RA, Amsterdam A, et al. Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol. 2006 May;101(2):322-6. 摘要
70. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 601: tamoxifen and uterine cancer. Jun 2014 [internet publication].全文
71. Zhang ZH, Su PY, Hao JH, et al. The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies. Int J Gynecol Cancer. 2013 Feb;23(2):294-303. 摘要
72. Luo J, Beresford S, Chen C, et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer. 2014 Jul 22;111(7):1432-9.全文 摘要
73. Saed L, Varse F, Baradaran HR, et al. The effect of diabetes on the risk of endometrial cancer: an updated systematic review and meta-analysis. BMC Cancer. 2019 May 31;19(1):527.全文 摘要
74. Johnatty SE, Tan YY, Buchanan DD, et al. Family history of cancer predicts endometrial cancer risk independently of Lynch syndrome: implications for genetic counselling. Gynecol Oncol. 2017 Nov;147(2):381-7. 摘要
75. Bubien V, Bonnet F, Brouste V, et al; French Cowden Disease Network. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet. 2013 Jan 18;50(4):255-63. 摘要
76. Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012 May;27(5):1327-31.全文 摘要
77. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014 Sep-Oct;20(5):748-58.全文 摘要
78. Pothuri B, Ramondetta L, Eifel P, et al. Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers. Gynecol Oncol. 2006 Dec;103(3):948-51. 摘要
79. Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic diseases. Compr Physiol. 2012 Apr;2(2):1143-211.全文 摘要
80. Hidayat K, Zhou HJ, Shi BM. Influence of physical activity at a young age and lifetime physical activity on the risks of 3 obesity-related cancers: systematic review and meta-analysis of observational studies. Nutr Rev. 2020 Jan 1;78(1):1-18.全文 摘要
81. Alizadeh S, Djafarian K, Alizadeh M, et al. The relation of healthy and Western dietary patterns to the risk of endometrial and ovarian cancers: a systematic review and meta-analysis. Int J Vitam Nutr Res. 2020 Jun;90(3-4):365-75. 摘要
82. Liu ZY, Gao XP, Zhu S, et al. Dietary inflammatory index and risk of gynecological cancers: a systematic review and meta-analysis of observational studies. J Gynecol Oncol. 2019 May;30(3):e23.全文 摘要
83. Li H, Mao H, Yu Y, et al. Association between dietary fiber and endometrial cancer: a meta-analysis. Nutr Cancer. 2020;72(6):959-67. 摘要
84. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007 Nov;107(2):159-62. 摘要
85. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006 Jan 19;354(3):261-9.全文 摘要
86. Renaud MC, Le T. Clinical practice guideline no. 291 - epidemiology and investigations for suspected endometrial cancer. J Obstet Gynaecol Can. 2018 Sep;40(9):e703-11. 摘要
87. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Dec 2021 [internet publication].全文
88. Saso S, Chatterjee J, Georgiou E, et al. Endometrial cancer. BMJ. 2011 Jul 6;343:d3954. 摘要
89. Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and management of endometrial cancer. Am Fam Physician. 2016 Mar 15;93(6):468-74.全文 摘要
90. Pennant ME, Mehta R, Moody P, et al. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG. 2017 Feb;124(3):404-11.全文 摘要
91. Castellano T, Ding K, Moore KN, et al. Simple hysterectomy for cervical cancer: risk factors for failed screening and deviation from screening guidelines. J Low Genit Tract Dis. 2019 Apr;23(2):124-8. 摘要
92. Gredmark T, Kvint S, Havel G, et al. Histopathological findings in women with postmenopausal bleeding. Br J Obstet Gynaecol. 1995 Feb;102(2):133-6. 摘要
93. American College of Radiology. ACR appropriateness criteria: abnormal uterine bleeding. 2020 [internet publication].全文
94. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 734: the role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding. Obstet Gynecol. 2018 May;131(5):e124-9.全文 摘要
95. American Institute of Ultrasound in Medicine, American College of Radiology, American College of Obstetricians and Gynecologists, Society of Radiologists in Ultrasound. AIUM practice guideline for the performance of sonohysterography. J Ultrasound Med. 2015 Aug;34(8):1-6. 摘要
96. Larson DM, Johnson KK, Broste SK, et al. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol. 1995 Jul;86(1):38-42. 摘要
97. Huang GS, Gebb JS, Einstein, MH, et al. Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. Am J Obstet Gynecol. 2007 Mar;196(3):243.e1-5. 摘要
98. Schnatz PF, Guile M, O'Sullivan DM, et al. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol. 2006 Mar;107(3):701-8. 摘要
99. Oaknin A, Bosse TJ, Creutzberg CL, et al. Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Sep;33(9):860-77.全文 摘要
100. American College of Radiology. ACR appropriateness criteria: pretreatment evaluation and follow-up of endometrial cancer. 2020 [internet publication].全文
101. Chang MC, Chen JH, Liang JA, et al. 18F-FDG PET or PET/CT for detection of metastatic lymph nodes in patients with endometrial cancer: a systematic review and meta-analysis. Eur J Radiol. 2012 Nov;81(11):3511-7. 摘要
102. Kitajima K, Murakami K, Yamasaki E, et al. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer. Ann Nucl Med. 2008 Mar 3;22(2):103-9. 摘要
103. Sharma P, Kumar R, Singh H, et al. Carcinoma endometrium: role of 18-FDG PET/CT for detection of suspected recurrence. Clin Nucl Med. 2012 Jul;37(7):649-55. 摘要
104. Kadkhodayan S, Shahriari S, Treglia G, et al. Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: systematic review and meta-analysis of the literature. Gynecol Oncol. 2012 Oct 26;128(2):397-404. 摘要
105. Amant F, Mirza MR, Koskas M, et al. Cancer of the corpus uteri. Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:37-50.全文 摘要
106. Creasman WT, DeGeest K, DiSaia PJ, et al. Significance of true surgical pathologic staging: a Gynecologic Oncology Group Study. Am J Obstet Gynecol. 1999 Jul;181(1):31-4. 摘要
107. McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Jul;106(1):16-22. 摘要
108. Cho KR, Cooper K, Croce S, et al. International Society of Gynecological Pathologists (ISGyP) endometrial cancer project: guidelines from the Special Techniques and Ancillary Studies Group. Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S114-22.全文 摘要
109. Abu-Zaid A, Alomar O, Abuzaid M, et al. Preoperative anemia predicts poor prognosis in patients with endometrial cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021 Mar;258:382-90. 摘要
110. Abu-Zaid A, Alomar O, Baradwan S, et al. Preoperative leukocytosis correlates with unfavorable pathological and survival outcomes in endometrial carcinoma: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021 Sep;264:88-96. 摘要
111. Dinkel E, Mundinger A, Schopp D, et al. Diagnostic imaging in metastatic lung disease. Lung. 1990;168 Suppl:1129-36. 摘要
112. Davis SD. CT evaluation for pulmonary metastases in patients with extrathoracic malignancy. Radiology. 1991 Jul;180(1):1-12. 摘要
113. Clark TJ, Barton PM, Coomarasamy A, et al. Investigating postmenopausal bleeding for endometrial cancer: cost-effectiveness of initial diagnostic strategies. BJOG. 2006 May;113(5):502-10. 摘要
114. Smith-Bindman R, Kerlikowske K, Feldstein VA, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998 Nov 4;280(17):1510-7. 摘要
115. Gupta JK, Chien PF, Voit D, et al. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis. Acta Obstet Gynecol Scand. 2002 Sep;81(9):799-816.全文 摘要
116. Kinkel K, Kaji Y, Yu KK, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology. 1999 Sep;212(3):711-8. 摘要
117. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005 Aug 6-12;366(9484):491-505. 摘要
118. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Mar;92(3):744-51. 摘要
119. Creutzberg CL, van Putten WL, Koper PC, et al; PORTEC Study Group. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000 Apr 22;355(9213):1404-11. 摘要
120. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2015 Dec 2;27(1):16-41.全文 摘要
121. Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021 Jan;31(1):12-39.全文 摘要
122. Lancaster JM, Powell CB, Chen LM, et al; SGO Clinical Practice Committee. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2014 Sep 17;136(1):3-7. [Erratum in: Gynecol Oncol. 2015 Sep;138(3):765.] 摘要
123. Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet Gynecol Scand. 2011 May;90(5):437-44. 摘要
124. American College of Obstetricians and Gynecologists, Society of Gynecologic Oncology. ACOG practice bulletin no. 147: Lynch syndrome. Obstet Gynecol. 2014 Nov;124(5):1042-54.全文 摘要
125. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 727: cascade testing: testing women for known hereditary genetic mutations associated with cancer. Obstet Gynecol. 2018 Jan;131(1):e31-4.全文 摘要
126. National Institute for Health and Care Excellence. Testing strategies for Lynch syndrome in people with endometrial cancer. Oct 2020 [internet publication].全文
127. Fung MF, Reid A, Faught W, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol. 2003 Oct;91(1):154-9. 摘要
128. Love CD, Muir BB, Scrimgeour JB, et al. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol. 1999 Jul;17(7):2050-4. 摘要
129. Demirkiran F, Arvas M, Erkun E, et al. The prognostic significance of cervico-vaginal cytology in endometrial cancer. Eur J Gynaecol Oncol. 1995;16(5):403-9. 摘要
130. Bristow RE, Purinton SC, Santillan A, et al. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol Oncol. 2006 Nov;103(2):709-13. 摘要
131. Fiorelli JL, Herzog TJ, Wright JD. Current treatment strategies for endometrial cancer. Expert Rev Anticancer Ther. 2008 Jul;8(7):1149-57. 摘要
132. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: uterine neoplasms [internet publication].全文
133. Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer. 1987 Oct 15;60(8 Suppl):2035-41. 摘要
134. Marchocki Z, Cusimano MC, Clarfield L, et al. Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. Am J Obstet Gynecol. 2021 Oct;225(4):367.e1-39. 摘要
135. Nagar H, Wietek N, Goodall RJ, et al. Sentinel node biopsy for diagnosis of lymph node involvement in endometrial cancer. Cochrane Database Syst Rev. 2021 Jun 9;6(6):CD013021.全文 摘要
136. Bodurtha Smith AJ, Fader AN, Tanner EJ. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol. 2016 Nov 18;216(5):459-76.e10.全文 摘要
137. Soliman PT, Westin SN, Dioun S, et al. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol. 2017 May 18;146(2):234-9.全文 摘要
138. Rossi EC, Kowalski LD, Scalici J, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. 2017 Feb 1;18(3):384-92. 摘要
139. Holloway RW, Abu-Rustum NR, Backes FJ, et al. Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol. 2017 May 28;146(2):405-15.全文 摘要
140. Bogani G, Murgia F, Ditto A, et al. Sentinel node mapping vs. lymphadenectomy in endometrial cancer: a systematic review and meta-analysis. Gynecol Oncol. 2019 Jun;153(3):676-83. 摘要
141. How JA, O'Farrell P, Amajoud Z, et al. Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis. Minerva Ginecol. 2018 Apr;70(2):194-214. 摘要
142. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991 Jan;40(1):55-65. 摘要
143. Badger C, Preston N, Seers K, et al. Physical therapies for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003141.全文 摘要
144. Galaal K, Donkers H, Bryant A, et al. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev. 2018 Oct 31;(10):CD006655.全文 摘要
145. Zhang H, Cui J, Jia L, et al. Comparison of laparoscopy and laparotomy for endometrial cancer. Int J Gynaecol Obstet. 2012 Mar;116(3):185-91. 摘要
146. Obermair A, Janda M, Baker J, et al. Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: results from a randomised controlled trial. Eur J Cancer.2012 May;48(8):1147-53.全文 摘要
147. Lin F, Zhang QJ, Zheng FY, et al. Laparoscopically assisted versus open surgery for endometrial cancer - a meta-analysis of randomized controlled trials. Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1315-25. 摘要
148. de la Orden SG, Reza MM, Blasco JA, et al. Laparoscopic hysterectomy in the treatment of endometrial cancer: a systematic review. J Minim Invasive Gynecol. 2008 Jul-Aug;15(4):395-401. 摘要
149. Ju W, Myung SK, Kim Y, et al; Korean Meta-Analysis Study Group. Comparison of laparoscopy and laparotomy for management of endometrial carcinoma: a meta-analysis. Int J Gynecol Cancer. 2009 Apr;19(3):400-6. 摘要
150. Jørgensen SL, Mogensen O, Wu C, et al. Nationwide introduction of minimally invasive robotic surgery for early-stage endometrial cancer and its association with severe complications. JAMA Surg. 2019 Jun 1;154(6):530-8.全文 摘要
151. Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012 Mar 1;30(7):695-700.全文 摘要
152. Ind T, Laios A, Hacking M, et al. A comparison of operative outcomes between standard and robotic laparoscopic surgery for endometrial cancer: a systematic review and meta-analysis. Int J Med Robot. 2017 Dec;13(4):e1851.全文 摘要
153. Gaia G, Holloway RW, Santoro L, et al. Robotic-assisted hysterectomy for endometrial cancer compared with traditional laparoscopic and laparotomy approaches: a systematic review. Obstet Gynecol. 2010 Dec;116(6):1422-31. 摘要
154. Orton J, Blake P. Adjuvant external beam radiotherapy (EBRT) in the treatment of endometrial cancer: results of the randomised MRC ASTEC and NCIC CTG EN.5 trial. Paper presented at: 2007 meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL. Jun 1-5 2007. J Clin Oncol. 2007 Jun 20;25(18_Suppl):5504.全文
155. Mariani A, Dowdy SC, Cliby WA, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008 Apr;109(1):11-8. 摘要
156. Khoury-Collado F, Abu-Rustum NR. Lymphatic mapping in endometrial cancer: a literature review of current techniques and results. Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1163-8. 摘要
157. Frost JA, Webster KE, Bryant A, et al. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2017 Oct 2;(10):CD007585.全文 摘要
158. Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009 Jan 10;373(9658):125-36.全文 摘要
159. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008 Dec 3;100(23):1707-16. 摘要
160. Bristow RE, Zahurak ML, Alexander CJ, et al. FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival. Int J Gynecol Cancer. 2003 Sep-Oct;13(5):664-72. 摘要
161. Chi DS, Welshinger M, Venkatraman ES, et al. The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol Oncol. 1997 Oct;67(1):56-60. 摘要
162. Bristow RE, Zerbe MJ, Rosenshein NB, et al. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol. 2000 Aug;78(2):85-91. 摘要
163. Wortman BG, Creutzberg CL, Putter H, et al; PORTEC Study Group. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer. 2018 Oct 25;119(9):1067-74.全文 摘要
164. Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst. 2012 Nov 7;104(21):1625-34.全文 摘要
165. van den Heerik ASVM, Horeweg N, de Boer SM, et al. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. Int J Gynecol Cancer. 2021 Apr;31(4):594-604.全文 摘要
166. Lawrie TA, Green JT, Beresford M, et al. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers. Cochrane Database Syst Rev. 2018 Jan 23;(1):CD012529.全文 摘要
167. Nout RA, Putter H, Jürgenliemk-Schulz IM, et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer. 2012 Jul;48(11):1638-48.全文 摘要
168. Creutzberg CL, Nout RA, Lybeert ML, et al; PORTEC Study Group. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e631-8.全文 摘要
169. Nout RA, van de Poll-Franse LV, Lybeert ML, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol. 2011 May 1;29(13):1692-700.全文 摘要
170. Onsrud M, Cvancarova M, Hellebust TP, et al. Long-term outcomes after pelvic radiation for early-stage endometrial cancer. J Clin Oncol. 2013 Nov 1;31(31):3951-6.全文 摘要
171. Kwak YK, Lee SW, Kay CS, et al. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in pelvic radiation therapy with moderate dose. PLoS One. 2017 Aug 28;12(8):e0183339.全文 摘要
172. Klopp AH, Yeung AR, Deshmukh S, et al. Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology-RTOG 1203. J Clin Oncol. 2018 Jul 10;36(24):2538-44.全文 摘要
173. Mundt AJ, Murphy KT, Rotmensch J, et al. Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1154-60. 摘要
174. Einhorn N, Trope C, Ridderheim M, et al. A systematic overview of radiation therapy effects in uterine cancer (corpus uteri). Acta Oncol. 2003;42(5-6):557-61. 摘要
175. Vargo JA, Boisen MM, Comerci JT, et al. Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria. Gynecol Oncol. 2014 Nov;135(2):190-5. 摘要
176. Lanciano RM, Curran WJ, Jr., Greven KM, et al. Influence of grade, histologic subtype, and timing of radiotherapy on outcome among patients with stage II carcinoma of the endometrium. Gynecol Oncol. 1990 Dec;39(3):368-73. 摘要
177. de Boer SM, Powell ME, Mileshkin L, et al; PORTEC Study Group. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019 Sep;20(9):1273-85.全文 摘要
178. Yi L, Zhang H, Zou J, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in high-risk endometrial cancer: a systematic review and meta-analysis. Gynecol Oncol. 2018 Jun;149(3):612-9. 摘要
179. de Boer SM, Powell ME, Mileshkin L, et al; PORTEC Study Group. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Feb 12;19(3):295-309.全文 摘要
180. Randall ME, Filiaci V, McMeekin DS, et al. Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer. J Clin Oncol. 2019 Jul 20;37(21):1810-8.全文 摘要
181. Thigpen T, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001 Jan 15;19(2):364-7. 摘要
182. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999 Jun;17(6):1736-44. 摘要
183. Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Jan;92(1):10-4. 摘要
184. Skeel RT, Khleif S (eds). Handbook of cancer chemotherapy. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.
185. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007 Sep-Oct;17(5):964-78. 摘要
186. Polyzos NP, Pavlidis N, Paraskevaidis E, et al. Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: an overview of survival data. Eur J Cancer. 2006 Feb;42(3):319-26. 摘要
187. Slomovitz BM, Filiaci VL, Walker JL, et al. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: a GOG Foundation study. Gynecol Oncol. 2022 Mar;164(3):481-91. 摘要
188. Lentz SS. Endocrine therapy of endometrial cancer. Cancer Treat Res. 1998;94:89-106. 摘要
189. Martin-Hirsch PP, Bryant A, Keep SL, et al. Adjuvant progestagens for endometrial cancer. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD001040.全文 摘要
190. Sorbe B, Nordström B, Mäenpää J, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer. 2009 Jul;19(5):873-8. 摘要
191. Klopp A, Smith BD, Alektiar K, et al. The role of postoperative radiation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2014 May-Jun;4(3):137-44.全文 摘要
192. Jones E, Beriwal S, Beyer D, et al. An analysis of appropriate delivery of postoperative radiation therapy for endometrial cancer using the RAND/UCLA Appropriateness Method: executive summary. Adv Radiat Oncol. 2015 Dec 17;1(1):26-34.全文 摘要
193. Gunderson CC, Fader AN, Carson KA, et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012 May;125(2):477-82. 摘要
194. Baker JO. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol. 2012 Apr;125(1):263-70. 摘要
195. Nout RA, Smit VT, Putter H, et al; PORTEC Study Group. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010 Mar 6;375(9717):816-23. 摘要
196. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004 Jun 1;22(11):2159-66.全文 摘要
197. Miller D, Filiaci V, Gelming G, et al. Late-breaking abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Paper presented at: Society of Gynecologic Oncology 2012 Annual Meeting on Women's Cancer. Austin, TX. Mar 24-27 2012. Gynecol Oncol. 2012 Jun;125(3):771-3.全文
198. Nomura H, Aoki D, Michimae H, et al. Effect of taxane plus platinum regimens vs doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at a high risk of progression: a randomized clinical trial. JAMA Oncol. 2019 Jun 1;5(6):833-40.全文 摘要
199. Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev. 2012 Apr 18;(4):CD003916.全文 摘要
200. Geller MA, Ivy JJ, Ghebre R, et al. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol. 2011 Apr;121(1):112-7.全文 摘要
201. Lu SM, Chang-Halpenny C, Hwang-Graziano J. Sequential versus "sandwich" sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometroid adenocarcinoma. Gynecol Oncol. 2015 Apr;137(1):28-33. 摘要
202. Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med. 2019 Jun 13;380(24):2317-26.全文 摘要
203. Lu KH, Broaddus RR. Endometrial cancer. Reply. N Engl J Med. 2021 Feb 11;384(6):586. 摘要
204. Penson RT, Wenzel LB, Vergote I, et al. Quality of life considerations in gynecologic cancer. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S247-57. 摘要
205. Creutzberg CL, van Putten WL, Koper PC, et al; PORTEC Study Group. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003 May;89(2):201-9. 摘要
206. Jhingran A, Burke TW, Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1366-72. 摘要
207. Ho JC, Allen PK, Jhingran A, et al. Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol. 2015 Oct;139(1):40-6.全文 摘要
208. Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Jan;92(1):4-9. 摘要
209. Sjoquist KM, Martyn J, Edmondson RJ, et al. The role of hormonal therapy in gynecological cancers - current status and future directions. Int J Gynecol Cancer. 2011 Oct;21(7):1328-33. 摘要
210. Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 Study J Clin Oncol. 2017 May 10;35(22):2535-41.全文 摘要
211. O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 Study. J Clin Oncol. 2022 Mar 1;40(7):752-61.全文 摘要
212. O'Malley DM, Bariani GM, Cassier PA, et al. Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study. Gynecol Oncol. 2022 Aug;166(2):245-53.全文 摘要
213. Makker V, Colombo N, Casado Herráez A, et al; Study 309–KEYNOTE-775 Investigators. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022 Feb 3;386(5):437-48.全文 摘要
214. Duska LR, Berkowitz R, Matulonis U, et al. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol Oncol. 2005 Jan;96(1):198-203. 摘要
215. US Food and Drug Administration. FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer. Apr 2021 [internet publication].全文
216. European Medicines Agency. Jemperli (dostarlimab). Oct 2022 [internet publication].全文
217. ClinicalTrials.gov. Study of TSR-042, an anti-programmed cell death-1 receptor (PD-1) monoclonal antibody, in participants With advanced solid tumors (GARNET). NCT02715284. Nov 2022 [internet publication].全文
218. Kalinsky K, Hong F, McCourt CK, et al. Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial. JAMA Oncol. 2021 Feb 1;7(2):271-8.全文 摘要
219. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Jan 1;24(1):36-44.全文 摘要
220. Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev. 2018 May 15;(5):CD008830.全文 摘要
221. Rees M, Angioli R, Coleman RL, et al. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas. 2020 Apr;134:56-61.全文 摘要
222. Cella D, Huang H, Homesley HD, et al. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: results from GOG 184. Gynecol Oncol. 2010 Dec;119(3):538-42. 摘要
223. Zhou X, Yao Z, Bai H, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021 Sep;22(9):1265-74. 摘要
224. Naqash AR, Moey MYY, Cherie Tan XW, et al. Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the National Cancer Institute - Cancer Therapy Evaluation Program. J Clin Oncol. 2022 Oct 10;40(29):3439-52.全文 摘要
225. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: management of immunotherapy-related toxicities [internet publication].全文
226. Cancer Care Ontario Program in Evidence-based Care Gynecology Cancer Disease Site Group. Follow-up after primary therapy for endometrial cancer: a systematic review. Jan 2006 (endorsed Jun 2017) [internet publication].全文
227. Vergote I, Kjorstad K, Abeler V, et al. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer. 1989 Sep 1;64(5):1011-6. 摘要
内容使用需遵循免责声明